Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 May;39(5):503–510. doi: 10.1111/j.1365-2125.1995.tb04487.x

Influence of the dosing interval on prolactin release after remoxipride.

G Movin-Osswald 1, M Hammarlund-Udenaes 1, C Von Bahr 1, P Eneroth 1, K Walton-Bowen 1
PMCID: PMC1365057  PMID: 7669486

Abstract

1. The prolactin response following administration of the D2-dopamine receptor antagonist remoxipride was studied in eight healthy male volunteers. The purpose of the study was to investigate the duration of a refractory period of prolactin release following two doses of remoxipride. A further aim was to compare the prolactin response following remoxipride and thyrotropin release hormone (TRH) during the refractory period. The subjects received two 30 min intravenous (i.v.) infusions of remoxipride 50 mg with different time intervals between the two doses, in a randomized six period crossover design. The time intervals between the two remoxipride doses were 2, 8, 12, 24 and 48 h. On one occasion the remoxipride dose was followed by an i.v. injection of TRH after 2 h. 2. The plasma peak prolactin concentrations obtained after the first remoxipride dose correspond to a maximal release of prolactin according to earlier studies. A small second peak of prolactin was observed after 2 h. The release was gradually increased with longer time intervals between the consecutive doses. The refractory period for a second prolactin release similar to the first one after remoxipride was found to be 24 h for most of the subjects. 3. TRH resulted in a faster and higher increase in prolactin response of a shorter duration than after remoxipride administered 2 h after the first dose.

Full text

PDF
503

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Awad A. G., Lapierre Y. D., Jostell K. G. Selective dopamine D2 antagonist and prolactin response in acute schizophrenia--results from remoxipride studies. The Canadian Remoxipride Study Group. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(5):769–777. doi: 10.1016/0278-5846(90)90047-k. [DOI] [PubMed] [Google Scholar]
  2. Braddock L. E., Blake I. M. Neuroendocrine tests during treatment with neuroleptic drugs. II. The TRH test. Br J Psychiatry. 1981 Nov;139:404–407. doi: 10.1192/bjp.139.5.404. [DOI] [PubMed] [Google Scholar]
  3. Chouinard G. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity. J Clin Psychopharmacol. 1987 Jun;7(3):159–164. [PubMed] [Google Scholar]
  4. Chouinard G., Turnier L., Kallai-Sanfacon M. A. Remoxipride in schizophrenia: effects on plasma prolactin. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(5-6):599–603. doi: 10.1016/0278-5846(85)90024-7. [DOI] [PubMed] [Google Scholar]
  5. Cohen H., Pugeat M., Tourniaire J., Bertrand J. Unresponsiveness of prolactin to repeated injection of sulpiride in man. Eur J Clin Pharmacol. 1983;25(2):275–277. doi: 10.1007/BF00543803. [DOI] [PubMed] [Google Scholar]
  6. Collu R., Ducharme J. R., Eljarmak D., Marchisio A. M., Bertrand J., Sabbagh I., Guillaumot P., Cohen H. Postreceptorial refractoriness of prolactin release mechanisms. Can J Physiol Pharmacol. 1983 Jul;61(7):676–684. doi: 10.1139/y83-105. [DOI] [PubMed] [Google Scholar]
  7. Farde L., Grind M., Nilsson M. I., Ogenstad S., Sedvall G. Remoxipride--a new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers. Psychopharmacology (Berl) 1988;95(2):157–161. doi: 10.1007/BF00174501. [DOI] [PubMed] [Google Scholar]
  8. Frantz A. G. The regulation of prolactin secretion in humans. Front Neuroendocrinol. 1973;0(0):337–374. [PubMed] [Google Scholar]
  9. Grind M., Nilsson M. I., Nilsson L., Oxenstierna G., Sedvall G., Wahlén A. Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers. Psychopharmacology (Berl) 1989;98(3):304–309. doi: 10.1007/BF00451679. [DOI] [PubMed] [Google Scholar]
  10. Hays S. E., Rubin R. T. Differential prolactin responses to haloperidol and TRH in normal adult men. Psychoneuroendocrinology. 1981;6(1):45–52. doi: 10.1016/0306-4530(81)90047-0. [DOI] [PubMed] [Google Scholar]
  11. Hell K., Wernze H. Drug-induced changes in prolactin secretion. Clinical implications. Med Toxicol Adverse Drug Exp. 1988 Nov-Dec;3(6):463–498. doi: 10.1007/BF03259897. [DOI] [PubMed] [Google Scholar]
  12. Ho K. Y., Smythe G. A., Lazarus L. The interaction of trh and dopaminergic mechanisms in the regulation of stimulated prolactin release in man. Clin Endocrinol (Oxf) 1985 Jul;23(1):7–16. doi: 10.1111/j.1365-2265.1985.tb00177.x. [DOI] [PubMed] [Google Scholar]
  13. Härnryd C., Bjerkenstedt L., Gullberg B., Oxenstierna G., Sedvall G., Wiesel F. A. Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr Scand Suppl. 1984;311:75–92. doi: 10.1111/j.1600-0447.1984.tb06860.x. [DOI] [PubMed] [Google Scholar]
  14. Iversen E. Intra- and extravascular turnover of thyrotrophin-releasing hormone in normal man. J Endocrinol. 1988 Sep;118(3):511–516. doi: 10.1677/joe.0.1180511. [DOI] [PubMed] [Google Scholar]
  15. Jacobs L. S., Snyder P. J., Utiger R. D., Daughaday W. H. Prolactin response to thyrotropin releasing hormone in normal subjects. J Clin Endocrinol Metab. 1973 Jun;36(6):1069–1073. doi: 10.1210/jcem-36-6-1069. [DOI] [PubMed] [Google Scholar]
  16. L'Hermite M., Denayer P., Golstein J., Virasoro E., Vanhaelst L., Copinschi G., Robyn C. Acute endocrine profile of sulpiride in the human. Clin Endocrinol (Oxf) 1978 Sep;9(3):195–204. doi: 10.1111/j.1365-2265.1978.tb02200.x. [DOI] [PubMed] [Google Scholar]
  17. Lapierre Y. D., Nair N. P., Chouinard G., Awad A. G., Saxena B., Jones B., McClure D. J., Bakish D., Max P., Manchanda R. A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Acta Psychiatr Scand Suppl. 1990;358:72–77. doi: 10.1111/j.1600-0447.1990.tb05293.x. [DOI] [PubMed] [Google Scholar]
  18. Lewander T., Westerbergh S. E., Morrison D. Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr Scand Suppl. 1990;358:92–98. doi: 10.1111/j.1600-0447.1990.tb05297.x. [DOI] [PubMed] [Google Scholar]
  19. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  20. McMurdo M. E., Howie P. W., Lewis M., Marnie M., McEwen J., McNeilly A. S. Prolactin response to low dose sulpiride. Br J Clin Pharmacol. 1987 Aug;24(2):133–137. doi: 10.1111/j.1365-2125.1987.tb03153.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mongioì A., Aliffi A., Vicari E., Coniglione F., Scapagnini U., D'Agata R. Down-regulation of prolactin secretion in men during continuous thyrotropin-releasing hormone infusion: evidence for induction of pituitary desensitization by continuous TRH administration. J Clin Endocrinol Metab. 1983 May;56(5):904–907. doi: 10.1210/jcem-56-5-904. [DOI] [PubMed] [Google Scholar]
  22. Morrison D., Englund A., Lawrie V., Lewander T., Schlachet A., Westerbergh S. E. Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride. Acta Psychiatr Scand Suppl. 1990;358:164–169. doi: 10.1111/j.1600-0447.1990.tb05311.x. [DOI] [PubMed] [Google Scholar]
  23. Movin-Osswald G., Hammarlund-Udenaes M. Remoxipride: pharmacokinetics and effect on plasma prolactin. Br J Clin Pharmacol. 1991 Sep;32(3):355–360. doi: 10.1111/j.1365-2125.1991.tb03911.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Müller E. E., Locatelli V., Cella S., Peñalva A., Novelli A., Cocchi D. Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. Drugs. 1983 Apr;25(4):399–432. doi: 10.2165/00003495-198325040-00004. [DOI] [PubMed] [Google Scholar]
  25. Nair N. P., Lal S., Thavundayil J. X., Isaac I., Eugenio H., Achim A., Schwartz G., Guyda H. Effect of normal aging on the prolactin response to graded doses of sulpiride and to arginine. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(5-6):633–637. doi: 10.1016/0278-5846(85)90031-4. [DOI] [PubMed] [Google Scholar]
  26. Nilsson L. B. Determination of remoxipride in plasma and urine by reversed-phase column liquid chromatography. J Chromatogr. 1990 Mar 16;526(1):139–150. doi: 10.1016/s0378-4347(00)82491-3. [DOI] [PubMed] [Google Scholar]
  27. Ogren S. O., Hall H., Köhler C., Magnusson O., Lindbom L. O., Angeby K., Florvall L. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol. 1984 Jul 20;102(3-4):459–474. doi: 10.1016/0014-2999(84)90567-3. [DOI] [PubMed] [Google Scholar]
  28. Swartz Conrad M. Characterization of the Total Amount of Prolactin Released by Electroconvulsive Therapy. Convuls Ther. 1985;1(4):252–257. [PubMed] [Google Scholar]
  29. Tormey W. P., Buckley M. P., Taaffe W., O'Kelly D. A., Darragh A. Prolactin responsiveness to repeated decremental doses of sulpiride. Horm Metab Res. 1981 Aug;13(8):454–455. doi: 10.1055/s-2007-1019299. [DOI] [PubMed] [Google Scholar]
  30. Widerlöv E., Andersson U., von Bahr C., Nilsson M. I. Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. Psychopharmacology (Berl) 1991;103(1):46–49. doi: 10.1007/BF02244072. [DOI] [PubMed] [Google Scholar]
  31. Wiesel F. A., Alfredsson G., Ehrnebo M., Sedvall G. Prolactin response following intravenous and oral sulpiride in healthy human subjects in relation to sulpiride concentrations. Psychopharmacology (Berl) 1982;76(1):44–47. doi: 10.1007/BF00430753. [DOI] [PubMed] [Google Scholar]
  32. den Boer J. A., Verhoeven W. M., Westenberg H. G. Remoxipride in schizophrenia. A preliminary report. Acta Psychiatr Scand. 1986 Oct;74(4):409–414. doi: 10.1111/j.1600-0447.1986.tb06262.x. [DOI] [PubMed] [Google Scholar]
  33. von Bahr C., Wiesel F. A., Movin G., Eneroth P., Jansson P., Nilsson L., Ogenstad S. Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers. Psychopharmacology (Berl) 1991;103(4):443–448. doi: 10.1007/BF02244242. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES